

Junling Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9062334/publications.pdf>

Version: 2024-02-01

49
papers

583
citations

687363

13
h-index

677142

22
g-index

51
all docs

51
docs citations

51
times ranked

685
citing authors

#	ARTICLE	IF	CITATIONS
1	Utilizing New Prescription Drugs: Disparities among Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites. <i>Health Services Research</i> , 2007, 42, 1499-1519.	2.0	60
2	Effect of pharmacist intervention on herpes zoster vaccination in community pharmacies. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2013, 53, 46-53.	1.5	58
3	Disparities in Access to Essential New Prescription Drugs between Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites. <i>Medical Care Research and Review</i> , 2006, 63, 742-763.	2.1	41
4	Disparity Implications of Medicare Eligibility Criteria for Medication Therapy Management Services. <i>Health Services Research</i> , 2010, 45, 1061-1082.	2.0	36
5	Racial and Ethnic Disparities in Influenza Vaccination among Adults with Chronic Medical Conditions Vary by Age in the United States. <i>PLoS ONE</i> , 2017, 12, e0169679.	2.5	27
6	Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2015, 31, 2021-2029.	1.9	25
7	Racial and ethnic disparities in influenza vaccinations among community pharmacy patients and non-community pharmacy respondents. <i>Research in Social and Administrative Pharmacy</i> , 2014, 10, 126-140.	3.0	24
8	Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 596-606.	0.9	24
9	Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. <i>Current Medical Research and Opinion</i> , 2011, 27, 1303-1313.	1.9	20
10	The economic implications of the racial and ethnic disparities in the use of selective serotonin reuptake inhibitors. <i>Current Medical Research and Opinion</i> , 2007, 23, 853-863.	1.9	18
11	Pharmacists' acceptable levels of compensation for MTM services: A conjoint analysis. <i>Research in Social and Administrative Pharmacy</i> , 2011, 7, 383-395.	3.0	16
12	Comparison of first refill rates among users of sertraline, paroxetine, and citalopram. <i>Clinical Therapeutics</i> , 2006, 28, 297-305.	2.5	15
13	Conjoint analysis of patient preferences on Medicare medication therapy management. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2011, 51, 378-387.	1.5	14
14	Historical trend of disparity implications of Medicare MTM eligibility criteria. <i>Research in Social and Administrative Pharmacy</i> , 2013, 9, 758-769.	3.0	14
15	A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States. <i>Rheumatology and Therapy</i> , 2018, 5, 255-270.	2.3	13
16	Racial and ethnic disparities in meeting Part D MTM eligibility criteria among the non-Medicare population. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012, 52, e87-e96.	1.5	12
17	Racial and ethnic disparities in meeting MTM eligibility criteria among patients with asthma. <i>Journal of Asthma</i> , 2017, 54, 504-513.	1.7	12
18	Disparity implications of proposed 2015 Medicare eligibility criteria for medication therapy management services. <i>Journal of Pharmaceutical Health Services Research</i> , 2016, 7, 209-215.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Disparity implications of the Medicare medication therapy management eligibility criteria: a literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 201-216.	1.4	9
20	Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. <i>Research in Social and Administrative Pharmacy</i> , 2014, 10, 106-125.	3.0	9
21	Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 993-1003.	0.9	9
22	Medical Expenditure Panel Survey: A valuable database for studying racial and ethnic disparities in prescription drug use. <i>Research in Social and Administrative Pharmacy</i> , 2008, 4, 206-217.	3.0	8
23	A comparison of direct medical costs across racial and ethnic groups among children with cancer. <i>Current Medical Research and Opinion</i> , 2008, 24, 847-858.	1.9	8
24	Contingent valuation and pharmacists' acceptable levels of compensation for medication therapy management services. <i>Research in Social and Administrative Pharmacy</i> , 2015, 11, e121-e132.	3.0	8
25	Exploring employer perceptions of pharmacy technician certification in the community pharmacy setting. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1215-1219.	3.0	8
26	Effects of the Medicare Part D comprehensive medication review on medication adherence among patients with Alzheimer's disease. <i>Current Medical Research and Opinion</i> , 2021, 37, 1581-1588.	1.9	8
27	Racial/ethnic disparities in measure calculations for Part D Star Ratings among Medicare beneficiaries with diabetes, hypertension, and/or hyperlipidemia. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1469-1477.	3.0	8
28	Trends in Medicare Part D Medication Therapy Management Eligibility Criteria. <i>American Health and Drug Benefits</i> , 2015, 8, 247-55.	0.5	8
29	Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 97-107.	0.9	6
30	Effects of Specialty Pharmacy Care on Health Outcomes in Multiple Sclerosis. <i>American Health and Drug Benefits</i> , 2016, 9, 420-429.	0.5	6
31	Status of diabetes care among community pharmacy patients with diabetes: Analysis of the Medical Expenditure Panel Survey. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2010, 50, 478-484.	1.5	5
32	Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. <i>Journal of Pharmaceutical Health Services Research</i> , 2014, 5, 109-118.	0.6	5
33	Association Between Medication Adherence and Healthcare Costs Among Patients Receiving the Low-Income Subsidy. <i>Value in Health</i> , 2020, 23, 1210-1217.	0.3	5
34	Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility in non-Medicare population. <i>Research in Social and Administrative Pharmacy</i> , 2014, 10, 904-917.	3.0	4
35	A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting. <i>SAGE Open Medicine</i> , 2018, 6, 205031211876723.	1.8	4
36	Effects of medicare part d on disparity implications of medication therapy management eligibility criteria. <i>American Health and Drug Benefits</i> , 2014, 7, 346-58.	0.5	4

#	ARTICLE	IF	CITATIONS
37	Comparisons of changes over time in per capita health expenditures across racial and ethnic groups. <i>International Journal of Public Policy</i> , 2010, 6, 172.	0.1	3
38	Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 581-587.	2.6	3
39	Effects of the 2013 American College of Cardiology/American Heart Association guidelines on racial and ethnic disparities in statin treatment among diabetics. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 544-552.	3.0	3
40	Receipt of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers among Medicare beneficiaries with diabetes and hypertension. <i>Journal of Pharmaceutical Health Services Research</i> , 2014, 5, 67-74.	0.6	2
41	A comparison between the effects of drug costs and share of family income on drug costs in determining drug price. <i>Medicine (United States)</i> , 2021, 100, e26877.	1.0	2
42	Exploring racial and ethnic disparities in medication adherence among Medicare comprehensive medication review recipients. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 3, 100041.	1.0	2
43	OUP accepted manuscript. <i>Journal of Pharmaceutical Health Services Research</i> , 2021, 12, 502-508.	0.6	2
44	Impact of Medicare Part D on Racial and Ethnic Minorities. <i>Diversity and Equality in Health and Care</i> , 2016, 13, 326-333.	0.2	2
45	Predictive value positive of MTM eligibility criteria under MMA and ACA in identifying individuals with medication utilization issues. <i>Journal of Pharmaceutical Health Services Research</i> , 2018, 9, 393-401.	0.6	1
46	Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study. <i>Inquiry (United States)</i> , 2018, 55, 004695801879574.	0.9	1
47	Pharmacy students' intentions to utilize pharmacoeconomics, pharmacoepidemiology, and health outcomes in future jobs. <i>Currents in Pharmacy Teaching and Learning</i> , 2019, 11, 995-1001.	1.0	0
48	Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020, 7, 133-147.	2.3	0
49	Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Adherence.. <i>American Health and Drug Benefits</i> , 2021, 14, 101-109.	0.5	0